Navigation Links
Inverseon's Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet
Date:1/14/2009

SAN FRANCISCO, Jan. 14 /PRNewswire/ -- Inverseon, Inc. (http://www.inverseon.com) announces the receipt of a notice of allowance from the United States Patent Office covering its oral product INV102 for asthma. Additionally, a comment highlighting Inverseon's clinical asthma study was published in the January 10, 2009 issue of The Lancet.

"To our knowledge, this would be the first patent for the utilization of certain beta blockers for the treatment of asthma," commented Amie E. Franklin, PhD, of Inverseon. "A similar story played out 10 years ago in congestive heart failure where certain beta blocker drugs have become billion dollar products."

"The Lancet Comment on Inverseon's human asthma study combined with the notice of allowance from the US Patent Office represent important external validation of Inverseon's approach to asthma. We believe that our oral therapy has the potential to be a significant product," commented William J. Garner, MD, Chairman of Inverseon.

About Inverseon, Inc.

Inverseon's product development programs target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as asthma, COPD and pulmonary hypertension. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects "Paradoxical Pharmacology," based on the divergence of acute versus chronic effects of certain drugs in chronic diseases. For further information, please visit Inverseon's website at http://www.inverseon.com.

Forward-Looking Statement

This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

    Contact:
    William J. Garner, MD
    bill@inverseon.com
   http://www.inverseon.com
    (415) 440-7400

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Inverseon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
2. Visualizing asthma-causing immune cells at work
3. New consensus on work-related asthma
4. Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
5. New Patient Satisfaction Study With budesonide/formoterol Combination Therapy and fluticasone/salmeterol Combination Therapy in Adults With Asthma
6. Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows
7. Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the Dose of ICS
8. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
9. Allergy Standards LTD to Attend 2008 American Academy of Allergy, Asthma and Immunology Conference
10. FDA Grants Market Clearance to Aerocrine Inc.s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma
11. Drug Reduces Airway Mucus in Preclinical Asthma Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... portal. In response to client demand KbioBox developed a sophisticated “3 click” gene ... Both are accessible from KBioBox’s new website, https://www.kbiobox.com/ and powered ...
(Date:12/8/2016)... PRINCETON, N.J. , Dec. 8, 2016 ... late-stage biopharmaceutical company focused on developing and commercializing products ... medical need, announced today that it will be hosting ... 8:30-9:30 am ET on the origins of innate defense ... as a review of oral mucositis and the recently ...
(Date:12/8/2016)... DIEGO , Dec. 8, 2016   ... a leading commercial provider of clinically actionable liquid ... patients, announces that clinical data featuring its Target ... to tissue biopsy for the detection of actionable ... results from research sponsored by Sara Cannon Research ...
(Date:12/7/2016)... /PRNewswire/ - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical company ... products for the treatment of cancer, today announced ... Development Program with Cytovance Biologics ( Oklahoma ... antibody product. Supported by recent positive interim clinical ... ovarian cancer patients, OncoQuest has engaged Cytovance to ...
Breaking Biology Technology:
(Date:11/24/2016)... IRVINE, Calif. , Nov. 23, 2016 ... help endurance athletes and their trainers non-invasively measure ... Variability Index, Pulse Rate, and Respiration Rate in approximately ... Ember enables users easy and immediate access to key ... as part of a training regimen. ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ... Banks and Academics) market is to witness a value of ... the highest Compounded Annual Growth Rate (CAGR) of 10.75% is ... analysis period 2014-2020. North America is ... Europe at 9.56% respectively. Report ...
(Date:11/14/2016)... SARASOTA, Fla., Nov. 14, 2016  xG Technology, Inc. ... in providing critical wireless communications for use in challenging ... ended September 30, 2016. Management will hold a conference ... at 5:00 p.m. Eastern Time (details below). ... announced a $16 million binding agreement to acquire Vislink ...
Breaking Biology News(10 mins):